NT
Intellia Therapeutics, Inc.
NTLA · NASDAQ
$11.49 +0.26% (+$0.03)
1M -0.95%
Market Cap $1.61B
P/E Ratio -
Div. Yield -
ROE 57.79%
Piotroski F-Score Weak
3/9Valuation
41 /100
Fair P/B 2.21x
P/S 26.98x
P/FFO N/A
Growth
49 /100
Stable Book val. growth 18.40%
Rev. growth 9.09%
FCF growth N/A
Profitability
0 /100
Weak Op. margin 711.66%
Gross margin 46.48%
FCF margin 783.30%
Quality
1 /100
Poor ROA 46.66%
ROIC 52.86%
Asset turnover 0.07x
Debt
100 /100
Low Current ratio 6.65x
Debt/Equity 0.10x
Debt/Assets N/A
Stability
33 /100
Unstable EPS volatility 12.29%
Beta 1.82x
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na NTLA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
John Leonard
Employees
377
Headquarters
Cambridge
Nadcházející události
05 LIS
Earnings
Upcoming earnings report